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Abstract
DOES INCREASING FLOW TO A HIGH FLOW NASAL CANNULA AFFECT
MEAN AIRWAY PRESSURE IN AN IN VITRO MODEL?
Introduction: High-flow nasal cannulas (HFNC) have become popular with many
institutions for administration of oxygen (O2). HFNCs are also being used in pediatric
and neonatal populations for administration of continuous positive airway pressure
(CPAP) as a treatment for respiratory distress. Adult patients are being treated with
HFNCs in a effort to provide a high percentage of O2 and correct hypoxemia and other
related conditions. The purpose of this study was to examine the effect of increasing
flow via a HFNC to an in vitro model to examine the effect of flow on mean airway
pressure (MPAW).
Method: An in vitro model to simulate non-labored and labored spontaneous
breathing was developed using a Michigan Instrument Laboratory Test and Training
Lung (MIL TTL) driven by a Hamilton Galileo ventilator to produce a negatively based,
inspired tidal volume. Flow was introduced to the MIL TTL via a 41 French double
lumen endotracheal tube. Airway pressure measurements were observed via a pressure
monitoring port placed between the MIL TTL and the endotracheal tube and connected to
the auxiliary pressure monitoring port located on the front of the Galileo ventilator. A
Vapotherm 2000i with adult transfer chamber and adult cannula, a Fisher Paykel
Optiflow, and a generic HFNC consisting of a concha column and a Salter labs high-flow
cannula were tested at 20, 30, and 40LPM flowrates. Data was recorded using two
respiratory rates (12 and 24) and two peak flowrates (35 and 65LPM) to simulate nonlabored and labored breathing. All other parameters were unchanged and the I:E ratio
was consistent.
Data Analysis: SPSS 16.0 for Windows was used to analyze all data for this
study. Descriptive statistics, one-way analysis of variance (ANOVA), and post hoc
Bonferroni was used for this study. A p value less than 0.05 were considered significant.
Results: Average MPAW for all devices were increased at all three flowrates.
MPAW was highest at 40LPM flow producing 3.1cmH2O averaged for all HFNCs and
both respiratory patterns. The difference in MPAW produced by the three HFNCs were
also significant with at p=0.000 at all flow rates. Post hoc Bonferroni adjusted
probabilities further showed all device comparisons significant except for VapothermVapotherm Labored at 30 and 40 LPM flow rates and Vapotherm-Generic Labored at 20
LPM at p<0.05. These three comparisons were at p>0.05 and were statistically equal.
The generic HFNC produced the highest MPAW (3.5cmH2O).
Conclusion: Increased flow via a HFNC does increase MPAW. The Vapotherm,
Optiflow, and generic HFNC did not produce the same level of MPAW in this study.
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Chapter I
Introduction
Oxygen (O2) therapy is a simple task taught in the first days of respiratory therapy
education. The importance of O2 therapy is often overlooked by respiratory therapists
(RTs) who focus on other technical procedures. The indications for use are dictated by
signs and symptoms directly observed by caregivers. Oxygen is considered a drug thus
requiring a physician's order to prescribe it and a licensed practitioner to administer it.
However, the reality of O2 therapy is that it is often neglected until a patient's condition
worsens to a point that requires very high amounts or alternative methods of delivering it.
New methods of delivering oxygen via nasal cannula style devices have been gaining
popularity (Waugh & Granger, 2004). Devices range from simple and affordable to
specialized with high humidity. Humidification systems have become more efficient
allowing higher flows to be administered. Patient comfort and tolerability has been
improved for patients not able to cope with oxygen masks. As new technology leads to
the development of new oxygen delivery tools, RTs must alter their focus on an
overlooked therapy and learn to adapt high flows and high humidity to treat respiratory
disease processes. RTs must learn when to correctly use these new methods of high-flow
delivery to better serve the patients and the health care centers.
There are many reasons to examine high flow oxygen therapy. Health care
centers across the country are focused on shorter stays and infection prevention. Fiscal
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shortfalls have forced many hospitals and clinics to look for alternative therapies for
treatment. Hospital acquired infection (HAI) has become a major motivator for change in
practices. With the proper use of high-flow therapy in patients with adult respiratory
distress syndrome (ARDS), acute cardiogenic pulmonary edema (ACPE), or chronic
obstructive pulmonary disease (COPD), patients may have the opportunity to reduce the
need for more invasive procedures such as mechanical ventilation or bi-level positive
airway pressure (BiPAP). The net result of this is less opportunities for patients to
develop HAI which can increase the length of stay (LOS).
Mortality rates vary among different disease states. ACPE has a mortality rate of
21% (Fiutowski, Waszyrowski, Krzeminska-Pakula, & Kasprzak, 2008). When ACPE
requires mechanical intervention and is complicated with myocardial infarction (MI), the
mortality rate increases to 67% (Fiutowski et al., 2008). ARDS also has an exceptionally
high mortality rate; however, studies have shown some variance. When averaged, the
pooled mortality rate for ARDS is 43% (Zambon & Vincent, 2008). Attributed to this
high mortality rate is difficulty in treating ARDS and the complications that occur with
positive pressure ventilation (PPV). COPD is a costly pathology both fiscally and in the
number of lives lost. COPD is currently the fifth leading cause of death in the United
States and is expected to rise to the third leading cause of death by 2020 (Ai-Ping, Lee, &
Lim, 2005). COPD exacerbations are a leading cause of hospitalizations in the United
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States. The average cost per COPD patient per year who suffers an exacerbation and
becomes hospitalized is $6000 (Ai-Ping et al., 2005).
The primary administration route with high flow oxygen is with a nasal cannula.
This method is minimally obstructive and best tolerated by all patient populations. The
nasal cannula has required some modification for high flow application. Larger bores,
light weight materials, and adaptability to different flow generators are some of the
modifications that have occurred.
High flow nasal cannulas (HFNC) mode of operation has been questioned in the
literature. Is it the oxygen that elicits the positive effects of high flow therapy or is it the
pressure generated by the high flow (Finer, 2005)? Either factor has led to HFNCs
becoming very popular among neonatal and pediatric populations. High flow therapy has
demonstrated a clear therapeutic advantage in these populations reducing the need for
invasive respiratory machinery. But, is it possible to achieve a reduction of invasive
respiratory procedures in the adult population with the use of HFNCs? If possible this
would provide a cost efficient tool to treat respiratory distress.
Research is needed to determine the effect high flow has on adult patients. There
is a need to determine flow-rates so that flow from these devices may be used
appropriately and quickly. Pressure generated from high flow devices must be
determined so patient selection can occur. The education for respiratory staff must also
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be adequate as high flows alter breathing mechanics. The view of O2 therapy must
change from a supportive modality to an interventional therapy with the use of HFNCs.
Purpose
The purpose of this study was to examine the effect of nasal high flow gas therapy
on mean airway pressure (MPAW) in adult patients. The experimental study will be
carried out in vitro in lieu of using human subjects. Much can be learned by investigating
what happens when gas flow is manipulated to determine the effect of MPAW.
Study Questions
Two questions were addressed by the study. Does increasing flow increase MPAW
in an adult breathing model? The devices used in this study were the Vapotherm 2000i,
the Optiflow, and a nasal cannula device fabricated from general stock of a respiratory
care department. The results obtained from the 3 units were examined to determine if the
devices yielded the same results.
Significance
The product of high flow rates in spontaneous breathing persons is unknown. By
using an in vitro lung model in this study, it was possible to isolate the effect of high
flowrates during negative pressure ventilation. This study compared two commercial
products and a fabricated high flow system from standard respiratory stock to determine
if all 3 devices produced the same effect. This provided MPAW readings that could be
suggestive of actual pressures experienced by patients who utilize this therapy. This
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study controlled all variables including respiratory time constants allowing the
computation of mean airway pressure.
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Chapter II
A Review of Literature
The literature used to perform this literature review covers multiple areas: Low
flow therapy, high flow therapy, neonatal and pediatric respiratory care, humidified high
flow nasal oxygen, Vapotherm, and Optiflow. Literature was obtained using PubMed,
CINAHL, and Web of Science using search terms such as Vapotherm, high flow nasal
cannula, humidified high flow nasal cannula, high flow oxygen, and Optiflow. Very few
studies were found with regards to adult use. Data from neonatal and pediatric studies
were used for comparative means. The literature search was limited to the last 15 years;
however, literature from other countries will be used due to the lack of research in this
area on adult subjects.
Low Flow Therapy
Low flow oxygen therapy (LFT) is practiced in every hospital in the United
States. Administration of low flow therapy (LFT) includes devices such as nasal
cannulas, simple masks, and partial and non rebreather masks. Low flow oxygen devices
provide fixed flows that can result in a fraction of inspired oxygen (FiO2) that is "neither
precise or predictable" (Branson, Hess, & Chatburn, 1995, p. 56). People who are
oxygen sensitive can be affected by the non-precise FiO2 concentration especially in the
COPD population. It is known that if hypoxic drive is eliminated the result is death.
Branson et al. (1995) state the accepted FiO2 for a 6 liter per minute (LPM) nasal cannula
is 44%. However, current studies focusing on oxygen (O2) concentrations suggest
6

otherwise. According to one report, a 6LPM nasal cannula produces a FiO2 between 3666% with a mean of 47.9% (Wettstein, Shelledy, & Peters, 2005). This was performed
with a closed mouth breathing technique. Individuals within the study achieved a higher
FiO2 while breathing with their mouth open compared to those who breathed with their
mouths closed. The results from open mouth breathing at a liter flow of 6LPM were 4086% with a mean of 59.6% (Wettstein, et al., 2005). Previous studies have not agreed on
the effect of open mouth/closed mouth on FiO2. Wettstein's et al. (2005) methodology
attempted to correct criticism of previous studies. Contrary to name, a high flow nasal
cannula system (6-15LPM) does not use a blender for gas mixing and falls into the low
flow category. The reason is due to a variable FiO2 dependent upon patient breathing
style. The same principle discussed above applies to cannula systems that use flows
higher than 6LPM. Wettstein's et al. (2005) results found means of 69.8% and 80.6% on
a Salter Labs high flow nasal cannula with closed mouth and open mouth techniques
respectively. Because the Salter Labs high flow nasal cannula is limited to 15LPM flow
and by definition is a low flow device, it will not be used in this study. A closer
examination of high flow therapy will occur in the following section.
High Flow Therapy
High flow therapy (HFT) is a smaller part of O2 therapy. High flow devices
provide a fixed FiO2 independent of the flow which provides a known FiO2 at all times
(Branson, Hess, & Chatburn, 1995). High flow cannula systems such as the Vapotherm
and the Optiflow use a source gas from a blender to feed the system providing a precise
7

FiO2 regardless of the patients breathing style or pattern. Traditional HFT devices such
as the air entrainment mask or venti-mask use a manufactured air entrainment port to mix
oxygen with entrained room air to provide a calculated and predictable FiO2. HFT has
been the standard for hypoxic drive patients. Due to controlled FiO2, predictable oxygen
delivery to the patient can be monitored; therefore, the partial pressure of oxygen in
arterial blood (PaO2) threshold remains intact. The high flow nebulizer (HFN) device is
if often used with face tents or aerosol face masks and has been used in the post
anesthesia care units (PACU) for years. The advantage is that it provides humidity and
precise oxygen control. High flow systems as Vapotherm 2000i have been proven to
provide a very reliable FiO2 in patients who have high respiratory rates and increased
work of breathing (Wagstaff & Soni, 2007).
Vapotherm 2000i
An oxygen delivery device produced by Vapotherm
(Vapotherm, Annapolis, Maryland) has been able to cross
the threshold of delivering oxygen at a higher liter flow than
any other device. Vapotherm 2000i (Figure 1) is an oxygen
delivery device that can deliver a gas flow of up to 40LPM
while providing 100% relative humidity. The device is
indicated for patients who are able to maintain a normal
Figure 1. Vapotherm 2000i
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carbon dioxide level but are suffering from poor oxygenation (Price, Plowright,
Makowski, & Misztal, 2008). This could also aid in better ventilation perfusion
matching. The device consists of a temperature control unit, a vapor transfer cartridge, a
heated delivery tube, and a patient interface (Vapotherm 2000i, n.d.). Other items needed
are a medical gas blender and sterile water. The device functions by heating the sterile
water to a temperature of 33-43°C. Once at temperature, the gas water vapor enters the
disposable vapor transfer cartridge which is filled by hollow tubes. The mixed medical
gas travels through the tubes within the vapor transfer cartridge and is humidified with
the gas water vapor. It is then transported to the patient via a water jacketed circuit which
is also heated in order to prevent the loss of humidity of the inspired gas. In a study
performed by Waugh and Granger (2004), the Vapotherm produced 43.3 mgH2O/L for all
measured flowrates. The patient interface is separate and interchangeable of the delivery
tube. The patient interface is a nasal cannula with large nasal openings that is worn in the
same manner as a low-flow nasal cannula. The device can be used with neonates,
pediatric, and adult patients. Due to the high level of humidity, most patients are able to
tolerate the increased flows provided by the Vapotherm. It has been shown to reduce
respiratory rates, reduce the use of NiPPV, and the need for positive pressure ventilation
(PPV) (Calvano, Sill, Kemp, & Chung, 2008). Also, Turnbull (2008) demonstrated
through a collection of case studies how high flow nasal therapy can stop the progression
of respiratory decline and artificial ventilation.

9

Optiflow
Another device currently available is the Optiflow gas system (Fisher and Paykel,
Auckland, New Zealand). The Optiflow (Figure 2) can deliver up to 50LPM when
connected to a high flow source (Fisher and Paykel Healthcare: Patient Interfaces, n.d.).
Optiflow is adaptable to different flow generators. Optiflow may be driven via a highflow flowmeter or a blender just as other high flow
devices. However, Optiflow can also be used in
conjunction with continuous positive airway pressure
(CPAP) generators. This allows the Optiflow system
to be used in many different areas including the
home. A heater must also be used in conjunction
with this device. Used with a Fisher and Paykel
heater set at 37 degrees Celsius and a heated

Figure 2. Optiflow HFNC
(Fisher & Paykel Healthcare, 2009)

inspiratory limb, 44mgH2O/L of water content can be
delivered (Parke, McGuiness, & Eccleston, 2009). The Optiflow is a traditional heated
bath system incorporating no new design; however, it does allow increased flow over
traditional nasal cannula systems. The scope of this device is for adult patients and no
neonatal information existed in the literature. Clinically, these devices can be utilized to
treat many different pathologies.
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Clinical Uses
High-flow nasal oxygen is capable of treating numerous ailments. For the most
part, high-flow oxygen was viewed as a modality to provide supplemental oxygen to
hypoxic patients. Since the introduction of the Vapotherm 2000i, high-flow heated
oxygen has become a therapy within itself. Vapotherm has had a significant role in
treating chronic obstructive pulmonary disease (COPD) and asthma (Price, Plowright,
Makowski, & Misztal, 2008). The high flow may generate positive pressure that can help
alleviate collapsed or narrowed bronchioles allowing trapped gas to escape. Other
published uses of Vapotherm include ventilatory failure, congestive heart failure (CHF),
trauma, myocardial infarction (MI), and hypothermia (Turnbull, 2008). The suspected
reasoning why Vapotherm therapy helps treat the pathologies is due to the humidified
gas. Without the 100% humidity supplied to the gas by the Vapotherm unit, it is doubtful
that patients would be able to tolerate such high gas flows.
Vapotherm has gained popularity for treatment of hypothermia victims (Turnbull,
2008). Patients who suffer from low core body temperatures can inhale warm humidified
air into the thoracic cavity to help re-warm the body. Vapotherm allows the gas to be
heated from 33 to 43°C facilitating a controlled warm-up. Vapotherm can also be
utilized to enhance the transition from mechanical ventilation to spontaneous breathing
without artificial airway (Turnbull, 2008; Woodhead, Lambert, Clark, & Christensen,
2006). This has been reported for neonatal, pediatric, and adult patients. As reported by
Woodhead, Lambert, Clark, and Christensen (2006) no neonates given humidified high11

flow oxygen via Vapotherm required re-intubation. Along with the humidity provided by
Vapotherm, it is also believed that the generation of a higher than normal mean airway
pressure is a byproduct of the high liter flow which plays an active role in Vapotherm
therapy. Studies have shown an increase in mean airway pressure in patients who are on
Vapotherm therapy (Groves & Tobin, 2007). This phenomenon helps explain the success
in obstructive pathologies and CHF patients. COPD and asthma patients benefit from the
humidified gas but may benefit greater from the continuous positive airway pressure
(CPAP) generated by the high flows of Vapotherm (Ai-Ping, Lee, & Lim, 2005). By
increasing airway pressure, the bronchioles are stabilized thus allowing trapped air to
escape and reverse the condition of air trapping. Another health issue that Vapotherm
has been helpful in treating is the need for high FiO2 by patients suffering from mental
pathologies such as claustrophobia and dementia. Patients suffering from claustrophobia
generally may not tolerate oxygen by mask or noninvasive positive pressure ventilation
(NiPPV) due to the feeling of smothering caused by the mask touching the face.
Vapotherm provides the higher FiO2 without the mask as long as the patient does not
breathe through their mouth. Patients suffering from impairments such as dementia often
instinctively remove oxygen devices from their face. In one such case described by
Calvano, Sill, Kemp, and Chung (2008), a patient who did not tolerate oxygen mask
therapy to treat hypoxemia was placed on Vapotherm with a significant improvement in
the measured PaO2 and observed respiratory rate.
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HFNC may be used to treat many different pathologies. Evidence exists
supporting the role of high humidity in this therapy's success. However, if positive
pressure is generated by HFNC, then positive pressure must also be considered as an
element leading to the success of this therapy.
High Flow Generates Positive Pressure
Current modalities are changing the methods of healthcare delivery. Patients in
the past suffering from respiratory failure had only one choice, the ventilator; however,
with the development of noninvasive ventilation (NIV), the pathway to recovery for
many has changed. NIV requires cooperative patients who will tolerate wearing a tightly
fitted mask. If they are unable to tolerate the mask, their only alternative is invasive
ventilation. NIV uses high flow rates and a sealed mask to generate pressure to augment
ventilation. If positive pressure is generated by high flow nasal oxygen, an alternative
delivery method may increase the tolerance of NIV.
The Vapotherm 2000i has not been used in any published studies to determine if
positive pressure is generated with adult subjects. However, research does exist detailing
that Vapotherm produces positive pressure in neonatal and pediatric subjects. Calvano,
Sill, Kemp, and Chung (2008) note in their literature review that high flow nasal oxygen
has been proven to be equivalent to noninvasive CPAP therapy in pediatrics. This is also
the conclusion arrived in a similar study performed on neonates (Sreenan, Lemke,
Hudson-Mason, & Osiovich, 2001). The positive pressure generated by high flow nasal
therapy is variable and patient dependent. Many factors weigh on the degree of positive
13

pressure produced. Open mouth, closed mouth, respiratory rate, volume of breath, and
depth of cannula in nares can influence the level of positive pressure.
The Optiflow has been the focus of two published studies. All studies have been
performed outside the United States. The Australian study concluded that high flow
nasal oxygen produces an increased oropharyngeal pressure when compared to
conventional therapies (Groves & Tobin, 2007). A similar study performed by Auckland
City Hospital in Auckland, New Zealand concluded the same results (Parke, McGuiness,
& Eccleston, 2009). Groves and Tobin (2007) used 5 healthy males and 5 healthy
females placed on Optiflow system at flows starting at 0LPM up to 60LPM.
Measurements taken via a 10 French nasal catheter were recorded. They concluded that
increasing nasal flow also increases oropharyngeal pressure. Their research concluded
that breathing with a closed mouth generates 5.5 cmH2O pressure at 40LPM flow and 7.4
cmH2O at 60LPM (Groves & Tobin, 2007). Adult male pressures were less than adult
female pressures which may be attributed to nasal orifice size.
Parke, McGuiness, and Eccleston (2009) conducted a study using 15 post cardiac
operative patients for the study group. This group had a 10 French nasal catheter placed
while under anesthesia. Recordings were made the morning following surgery with no
set amount of time stated. Their results were presented as group mean only and showed a
mean oropharyngeal positive pressure of 2.70 cmH2O at 35LPM with closed mouths
(Parke et al., 2009). The study concluded that high flow nasal therapy produces low level
positive airway pressure at 35LPM. Park et al. (2009) also noted that the variability of
14

airway pressures observed in their study was most likely attributed to varying nasal
orifice sizes. However, generation of positive airway pressure resulted in the generation
of positive end expiratory pressure (PEEP) and increased MPAW.
Mean Airway Pressure
Mean airway pressure (MPAW) is generally associated with mechanical ventilation.
It is a relationship of pressure over time. However, if airway pressure is increased by a
noninvasive source, theoretically MPAW is also increased. The difficulty in calculating
MPAW in noninvasive ventilatory patients is the unknown time constants associated with
spontaneous respiration. MPAW is defined as inspiratory time (TI) multiplied by peak
inspiratory pressure (PIP) plus expiratory time (TE) multiplied by peak end expiratory
pressure (PEEP) divided by total cycle time (Ttot). The written formula appears as MPAW=
(TI x PIP)+(TE x PEEP)/Ttot. Without the ability to set or measure the time constants
associated with breathing, MPAW calculations are not possible.
Conclusion
HFNC is an accepted treatment for hypoxia. HFNC also has been documented to
produce CPAP in pediatric and neonatal applications. A limited body of literature exists
supporting its use in the adult population. HFNC has the potential to lower the cost of
treatment for some diseases. It reduces cost by preventing the need for invasive
procedures such as mechanical ventilation and the associated risk of infections. But
many questions remain as to how best use this therapy in the adult environment. Further
study of the pressure effect produced by HFNC is needed. Starting points for flow
15

selection need to be determined so that MPAW can be targeted to treat specific pathologies.
There is a need to compare the Vapotherm 2000i and the Optiflow to determine if both
devices produce the same outcome. Many questions concerning this emerging therapy
remained unanswered.
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CHAPTER III
RESEARCH METHODS
The purpose of this study was to measure pressures associated with high flow
nasal cannula (HFNC) system during spontaneous breathing. Specifically, the study is
designed to address the question does increasing flow to a HFNC increase mean airway
pressure. Spontaneous breathing is associated with negative intrathoraic pressure. To
produce this type of respirations in vitro, a ventilator was used to ventilate one side of a
double lung model. Figure 3 demonstrates the set-up used for this study. Side A of the
double lung was positive pressure ventilated which mechanically raised side B of

Figure 3. Testing Model set-up with Optiflow HFNC
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artificial lung via a board clamped at the outer edges. Side B of the artificial lung
represents a negative pressure model. A double lumen 41 French oral endotracheal tube
(Figure 4) trimmed to the upper cuff was used to simulate the nares of the model. The
cuff was inflated to seal inside a 6 inch 22mm internal diameter vinyl tubing. A 22mm
outside diameter pressure line adaptor was connected to the other end of vinyl tubing
which was connected to the test lung
tubing. The HFNC was setup to
manufacturer specifications minus
humidity and powered by a high flow
oxygen flow meter designed to deliver flow
up to 80 liters per minute (LPM). The
Figure 4

nasal cannula was positioned via a clamp so

41 French double lumen endotracheal tube

that the cannulas were slightly inserted into
the in vitro nose. Flow through the HFNC system was manipulated at 20, 30, and 40
LPM flowrates. Measurements were taken via small bore oxygen tubing by the auxiliary
pressure monitor port on the Galileo ventilator.
Lung Model
In this study, an in vitro lung model as seen in Figure 3 was used to simulate adult
patient respiration. The Michigan Instruments Labs (MIL) Dual Adult TTL Lung
(Michigan Instruments, Inc. Grand Rapids, Michigan) was used in conjunction with an
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adult ventilator. The MIL adult lung has 2 independent chambers that can be
independently ventilated. Compliance was manipulated independently. Compliance of
0.5L/cmH2O was used for the study for both the positive pressure and negative pressure
chambers. No resistors were used in this study.
Ventilator
A Hamilton Galileo Gold ventilator (Hamilton Medical, Inc. Reno, Nevada) was
used with a standard 72 inch adult circuit (Figure 5). The Hamilton Galileo is a
microprocessor based ventilator. The Galileo was chosen because of an accessory
auxiliary pressure port located on the front of the ventilator. Ventilator settings were
chosen to mimic adult ventilation. Two sets of
parameters were chosen to simulate non-labored
and labored breathing. Non-labored parameters
were respiratory rate of 12, 450mL tidal volume,
no PEEP, 21% oxygen, and a flowrate of 35LPM
which yielded an inspiratory/expiratory (I:E) ratio
of 1:3.1. Labored parameters were a respiratory
rate of 24, 450ml tidal volume, no PEEP, 21%
oxygen, and a flowrate of 65LPM which yielded a
I:E ratio of 1:2.8. The Hamilton Galileo was
Figure 5

calibrated per manufacturer guidelines before use

Hamilton Galileo Gold
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in this study. The ventilator was connected directly to side A of the MIL lung.
Parameters manipulated during this study were respiratory rate and flow. Flow was
manipulated to produce inspiration/expiration ratios (I:E Ratio) similar to normal
breathing. All other parameters remained constant.
Fabricated High-flow Device
The fabricated high-flow device seen in Figure 6 was constructed of materials
found available in a respiratory therapy department. The device consisted of products
manufactured by Hudson RCI (Teleflex Medical, Research Triangle Park, NC). The
device consisted of Hudson Concha
4 heater column with nipple
adaptor. This was connected to a
heated wire circuit also
manufactured by Hudson RCI. The
circuit was connected to a Salter

Figure 6
Generic HFNC

Labs HFNC (Salter Labs, Inc.

Arvin, CA) via a second nipple adaptor. The Salter Labs HFNC was chosen because it is
designed to deliver flows of 6-15 LPM.
Data Collection
Data was collected in accordance to the protocols listed in Appendix A and
Appendix B. Data was monitored via the Galileo ventilator. Three pressures were
recorded for this study. The minimum pressure (PMIN) represents the lowest pressure
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generated during the breath. Positive end-expiratory pressure (PEEP) and positive
inspiratory Pressure (PIP) were recorded. After the warm-up periods described by the
protocols were completed, recordings from 12 breaths were recorded.
From the data collected, mean airway pressure (MPAW) was able to be calculated.
Calculations were possible due to the known time constants of the recorded breaths.
Using the formula MPAW= (TI x PIP)+(TE x PEEP)/Ttot, MPAW was calculated for all
breaths.
Data Analysis
Data was analyzed using SPSS for Windows (version 16.0). The data analysis
included a one way ANOVA, a Bonferroni test, and descriptive statistics.
Conclusion
The research methods were directed by two study questions: (1) Does increasing
flow through a high flow nasal cannula increase MPAW? and (2) does the devices used in
this study yield results that are statistically different? A Hamilton Galileo, with auxiliary
port pressure monitoring, was used in this study. The Hamilton Galileo is capable of
measuring pressures to the tenth of a centimeter of water pressure. A MIL adult dual test
lung was also used in this study. The ventilator was used to ventilate one chamber of the
test lung which triggered a spontaneous negative breath in the second chamber via a
clamped board. A 41 French double lumen endotracheal tube trimmed to the high cuff
was used to simulate the nares. The study focused on the Vapotherm 2000i with adult
transfer chamber, Optiflow, and a generic built high flow nasal cannula system.
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Chapter IV
Results
The primary focus of this study was the effect of increasing flow to a high flow
nasal cannula (HFNC) on mean airway pressure (MPAW). The research was also directed
by the research question: Are the outputs of two commercial devices, the Vapotherm
2000i and Optiflow, and a high flow system constructed of available equipment from a
respiratory therapy department, statistically different?
Analysis was performed using descriptive statistics and a one way ANOVA. Post
hoc analysis utilizing a Bonferroni was also used. Descriptive statistics for non-labored
and labored breathing can be seen in Table 1 and 2.
Non-Labored Statistics
N

Mean

Std. Deviation

Variance

FLOW20LPM

36

.467

.1265

.016

FLOW30LPM

36

1.503

.3282

.108

FLOW40LPM

36

2.981

.4880

.238

Table 1. Descriptive analysis of non-labored breathing by liter flow.
Labored Statistics
N

Mean

Std. Deviation

Variance

FLOW20LPM

36

.444

.0607

.004

FLOW30LPM

36

1.542

.1156

.013

FLOW40LPM

36

3.144

.1963

.039

Table 2. Descriptive analysis of labored breathing by liter flow.
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For this study, 72 MPAW calculations were recorded. As shown in Tables 1 and 2,
the statistical mean for all 3 flowrates were positive indicating MPAW was increased when
on HFNC. The statistical mean trends upward as flow increases. Figures 7 and 8
provides side by side comparison of the devices depicting MPAW for each device at the
three liter flows recorded for non-labored and labored breathing patterns.

Non-Labored Breathing Device Comparison
Mean Airway Pressure

4.0

3.5

3.5

3.1

3.0
2.3

2.5
1.9
2.0

VAPOTHERM

1.5
1.5
1.0
0.5

1.1

OPTIFLOW

0.6

0.5

GENERIC

0.3

0.0
20LPM

30LPM

40LPM

Liter Flow

Figure 7. Device Comparison of Mean Airway Pressure for
non-labored breathing pattern
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Labored Breathing Device Comparison
4.0
Mean Airway Pressure

3.4
3.5

3.1 3.0

3.0
2.5
1.7

2.0

VAPOTHERM

1.5 1.4

1.5
1.0

OPTIFLOW
0.4 0.4 0.5

GENERIC

0.5
0.0
20LPM

30LPM

40LPM

Liter Flow

Figure 8. Device Comparison of Mean Airway Pressure for
labored breathing pattern
One way ANOVA results can be found in Table 3. The overall effects were
significant F (5,66) = 191.481, 1237.704, and 1975.356 respective to liter flow. p =
0.000 for all flowrate comparisons. Further analysis via Bonferroni adjusted probabilities
can be found in Tables 4, 5, and 6. The Bonferroni adjusted probabilities determined all
comparisons were significant except for Vapotherm-Vapotherm Labored at 30 and 40
LPM flow rates and Vapotherm-Generic Labored at 20 LPM. These three comparisons
all were at the p > 0.05 level. At this level, the devices produced the same outcome in
regards to MPAW. All other comparisons had significant differences at the p < 0.05 level.
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Table 3. One way ANOVA analysis
Sum of Squares
FLOW20LPM

FLOW30LPM

Mean Square

F

Between Groups

.653

5

.131

Within Groups

.045

66

.001

Total

.698

71

4.219

5

.844

.045

66

.001

4.264

71

10.101

5

2.020

.068

66

.001

10.169

71

Between Groups
Within Groups
Total

FLOW40LPM

df

Between Groups
Within Groups
Total

191.481

.000

1237.704

.000

1975.356

.000

Table 4. Pairwise analysis of 20LPM flowrate data
VT20
OF20 GEN20 VT20LAB OF20LAB GEN20LAB
VT20

.2000* -.1000* .1083*

OF20

-.2000*

GEN20

.1000*

.30008

VT20LAB

-.1083*

.0917* -.2083*

OF20LAB

-.0667*

.1333* -.1667* .0417*

GEN20LAB .0083t

-.3000* -.0917*

.2083* -.0917

.2083*

.1167*

.0667*

-.0083t

-.1333*

-.2083*

.1667*

.0917*

-.0417*

-.1167*
-.0750*

.0750*

VT20=Vapotherm 20LPM OF20=Optiflow 20LPM
GEN20=Generic 20LPM
VT20LAB=Vapotherm 20LPM Labored
OF20LAB=Optiflow 20LPM Labored
GEN20LAB=Generic 20LPM labored *p<0.05 t = p > 0.05
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Sig.

Table 5. Pairwise analysis of 30LPM flowrate data
VT30
OF30
GEN30 VT30LAB OF30LAB

GEN30LAB

VT30

.3917*

-.4000*

.0000t

.0667*

-.1917*

-.7917*

-.3917*

-.3250

-.5883

.4000*

.4667*

.2083

.0667*

-.1917*

OF30

-.3917*

GEN30

.4000*

.7917*

VT30LAB

.0000t

.3917*

-.4000*

OF30LAB

-.0667*

.3250*

-.4667*

-.0667*

.5833*

-.2083*

.1917*

GEN30LAB .1917*

-.2583*
.2583*

VT30=Vapotherm 30LPM OF30=Optiflow 30LPM
GEN30=Generic 30LPM
VT30LAB=Vapotherm 30LPM Labored
OF30LAB=Optiflow 30LPM Labored
GEN30LAB=Generic 30LPM labored *p<0.05 t = p > 0.05

Table 6. Pairwise analysis of 40LPM flowrate data
VT40
OF40
GEN40 VT40LAB OF40LAB GEN40LAB
VT40

.7583*

-.4000*

.0083t

OF40

-.7583*

GEN40

.4000*

1.1583*

VT40LAB

-.0083t

.7500*

-.4083*

OF40LAB

-.1583*

.6000*

-.5583*

GEN40LAB .3000*

-1.1583* -.7500*
.4083*

.1583*

-.3000*

-.6000*

-1.0583*

.5583*

.1000*

.1500*

-.3083*

-.1500*

1.0583* -.1000*

.3083*

-.4583*
.4583*

VT40=Vapotherm 40LPM OF40=Optiflow 40LPM
GEN40=Generic 40LPM
VT40LAB=Vapotherm 40LPM Labored
OF40LAB=Optiflow 40LPM Labored
GEN40LAB=Generic 40LPM labored *p<0.05 t = p > 0.05
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Conclusion
In conclusion, the results of this study answered the two questions. As seen in
Figure 1, HFNC systems produce a positive MPAW at the 20, 30, and 40LPM flowrates.
The one way ANOVA analysis indicates that there is a statistical significance in the
outcomes of the devices used in this study. The generic HFNC system produced a MPAW
consistently higher than the Vapotherm or Optiflow at all liter flows. All values for the
generic system were significantly greater when compared to other devices.
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Chapter V
Discussion
This study was designed to answer two research questions. The primary question
was to evaluate the relationship of flow via a high flow nasal cannula (HFNC) on mean
airway pressure (MPAW) in an adult model. The second question was to evaluate the
MPAW pressures generated by three HFNC systems. The study compared the Vapotherm
2000i, the Optiflow, and a system constructed of different parts stocked in a hospital
respiratory department.
Using the in vitro model, breathing was simulated and recordings were made
using three different high flow systems. Average MPAW for all three liter flows were
greater than 0 cmH2O for all systems. MPAW averages for 20LPM, 30LPM, and 40LPM
were 0.5cmH2O, 1.5cmH2O, and 3.1cmH2O respectively. These averages are inclusive
of both the unlabored and labored groups. It can be concluded that HFNC increases
MPAW in the in vitro model. It can also be deducted that HFNC produces PEEP in this
model based on the mathematical formula MPAW= (TI x PIP)+(TE x PEEP)/Ttot. In this
study, the expiratory time (TE) was 2.8 to 3.1 times greater than the inspiratory time (TI).
Therefore, for MPAW to be positive PEEP must be present.
Side by side comparison of the devices at the different flow rates yielded
additional information. The three devices were compared by the MPAW delivered. The
two commercially available devices, Vapotherm and Optiflow, were compared and
determined that Vapotherm produces a higher MPAW than Optiflow in this study. When
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the generic HFNC system was compared to the commercial systems, the generic
delivered a higher MPAW than either the Vapotherm or Optiflow. At 40LPM, the highest
MPAW was produced and the generic system produced the highest average pressure at
3.65cmH2O. Vapotherm averaged 3.1cmH2O and Optiflow produced 2.65cmH20. One
way ANOVA also showed the differences were statistically significant as the liter flow
increased. As flow increased, the F ratio also increased. Post hoc Bonferroni adjusted
probabilities were compared in pairwise tables. When comparing the three devices, it can
be concluded that the generic system was superior in terms of MPAW and the Vapotherm
produced a higher MPAW than the Optiflow system in this study.
This study controlled all variables in order to isolate MPAW. Similar studies using
HFNC systems used human subjects and were unable to calculate MPAW (Groves &
Tobin, 2007). Parke, McGuiness, and Eccleston (2009) performed a study that concluded
35LPM flow via the Optiflow generated 2.70cmH2O of MPAW; however, stated in the
study as a limitation was the uncertainty that the pressure was MPAW even though the
researchers named the pressure MPAW. Parke et al. (2009) did refer to the recorded
pressure as MPAW. Parke et al. (2009) recordings at 35LPM fall between the two data
averages recorded in this study. However, the in vitro model study average MPAW
pressures for 30 and 40LPM are 1.5cmH2O and 3.1cm H2O respectively and the two
studies do correlate. Unfortunately, Parke et al. (2009) did not include data to reproduce
their findings at the liter flow described. Respiratory rates, tidal volumes, and breathing
styles were unknown for the Parke et al. (2009) study.
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Groves and Tobin (2007) utilized the Optiflow system at flows of 40 and 60LPM.
They used healthy males and females and recorded average expiratory pressures of
5.5cmH2O and 7.4cmH2O, respectively. When compared to the in vitro study at 40LPM,
a significant difference can be seen. The Optiflow system averaged 2.7cmH2O at 40LPM
using the in vitro lung model. The generic system produced the highest average MPAW at
3.5cmH2O which is still lower than the study conducted by Groves and Tobin (2007).
Groves and Tobin measured oropharyngeal pressure and not MPAW. This could be
attributed to differences in pressures recorded. This study isolated variables such as time
constants in order to calculate MPAW. Groves and Tobin (2007) used healthy human
subjects to collect data. Pressures presented by Groves and Tobin cannot be a calculated
MPAW average as spontaneous breathing subjects cannot breathe in a manner to isolate
inspiratory and expiratory time constants.
HFNCs do not function as a normal nasal cannula. It is capable of providing a
higher FiO2 concentration as well as increased pressures. The increased flow generates
resistance to expiratory flow thereby increasing MPAW. Increased MPAW can be utilized to
treat patients suffering from ailments such as COPD exacerbations, congestive heart
failure (CHF), or hypoxic failure. Correct utilizations of the therapy are also important
and an understanding of the physiological effects must be understood by respiratory
therapists using this therapy.
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Limitations
There are limitations to any study performed. Many limitations have been
identified for this study. The following limitations have been taken into account by the
researcher for this study.
1.

In vitro study findings can be difficult to generalize due to the fact that a
bench model is not an actual person. The simulator may not model the actual
condition being studied.

2. The artificial nose and airway is not physiologically correct. In an actual
human subject, the flow introduced by a HFNC will meet a much higher level
of resistance as the flow is introduced to the human nose. This could account
for the differences.
3. The design of the artificial nose could also influence flow in a laminar pattern.
It is reasonable to consider that flow through a human nose may be more
turbulent in nature and thereby increase resistance to expiratory flow.
4. The model is not to scale in terms of length when compared to a physiological
model. The model is constructed of noncompliant smooth vinyl with little
resistance. The tracheal rings that are present in a human subject could
increase resistance or influence turbulent flow.
5. Orifice sizes of the cannulas were not measured for this study. There is a
possibility that the nasal cannulas could have different orifice sizes which
could influence MPAW levels.
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6. No tests included humidity. Vapotherm and Optiflow are both documented to
provide 100% relative humidity (Waugh & Granger, 2004; Parke, McGuiness,
& Eccleston, 2009). Therefore, the tests were not conducted using humidity.
The generic system was not tested for relative humidity produced. It is a
possibility that the comparison is unreasonable as this system may fail to
deliver 100% relative humidity. Also, the humidified air may have a larger
molecular makeup when compared to the dry gas used in this study. The
larger molecular makeup of humidified gas could produce a higher MPAW.
Need for further Research
Further research evaluating HFNC systems should be performed to better
understand the effect in adult patients. A comparison study needs to be performed using
adult subjects to further evaluate the devices used in this study. There is a lack of
literature pertaining to adults and HFNC therapy.
Research exists in the neonatal and pediatric populations where HFNC therapy
has found a high level of success. Kubicka, Limauro, and Darnall (2008) performed a
bench study and human trials with HFNC on neonates. Bench study measurements were
conducted with an anesthesia bag with an estimated leak to represent a patient's nose and
mouth. They observed HFNC producing 4.5cmH2O at 8.0LPM flow in vitro (Kubicka et
al., 2008). When the study was transitioned to in vivo they discovered that 4.0LPM flow
generated 4.3 to 4.8cmH2O oral cavity pressure with a closed mouth (Kubicka et al.,
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2008). Weiner et al. (2008) also reported oral cavity pressures ranging from 2.5 to
3.5cmH2O at the 5.0LPM flow.
For this study, however, it must be noted that it is difficult to compare adults to
neonates due to differences in physiological features. Many nasal cannulas used in highflow therapy are snug in the nares which may contribute to a higher level to pressure.
Also, the nasopharyngeal cavity is much smaller and may provide a lower level of
resistance. Adult patient nares have a larger opening and are not likely to be occluded by
a nasal cannula. Adults also have a much larger nasopharyngeal cavity to distribute the
flow generated by HFNC. Due to these physiological differences, neonatal and pediatric
studies do not offer an effective comparison for adult interpretation.
There is also a need for an evaluation of devices constructed to deliver high flow
therapy to determine if they are capable of delivering the high levels of humidity that the
Vapotherm and Optiflow systems are capable of. This therapy is a combination of two
therapies, humidity and high flow. Any system constructed must be capable of providing
both.
Conclusion
HFNCs are a new spin on an old device. They provide a level of humidity that
was once only delivered with closed systems. HFNCs deliver flows that exceed the scale
on most flow meters. They deliver FiO2 percentages higher than some of the masks that
have been used for many years in respiratory care. It cannot be assumed by respiratory
therapists that they only deliver oxygen.
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As this study has shown, HFNCs have a profound physiological effect. HFNC
produce PEEP and increase MPAW. As flow increases, MPAW also increases. This has the
potential to be an effective therapy for numerous ailments in the adult population. HFNC
profoundly affected care in the pediatric and neonatal populations. HFNC does possess
the ability to do the same for adult patients.
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Appendix A
Protocol
Non-labored Breathing

1. Power on Galileo Ventilator

2. Run manufacturer flow-sensor calibration
3. Program ventilator with selected parameters
a. Respiratory rate of 12
b. Tidal volume 400
c. Flow of 35LPM
i. Produces I:E of 1:3.1
d. Sine Waveform
e. Oxygen 21%
f. No PEEP
4. Connect ventilator circuit to positive pressure side of test lung
a. Lung compliance set at 0.5 L/cmH2O
5. Activate auxiliary pressure port
a. Connect auxiliary pressure line to front of ventilator
b. Connect auxiliary pressure line to adaptor placed in negative airway
6. Start ventilator and allow to cycle for 1 minute
7. Start Measurement of control with no cannula at the orifice of double lumen tube
Vapotherm

1. Recalibrate Galileo flowsensor
2. Allow to cycle for 1 minute
3. Connect Vapotherm unit to H cylinder and turn flow to 20 LPM via high flow
flow-meter
4. Position adult nasal Vapotherm cannula with clamp stand so that nasal prongs rest
inside double lumen tube
5. After cannula in place cycle ventilator for 1 minute
6. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)
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7. Recalibrate Galileo flowsensor
8. Allow to cycle for 1 minute
9. Connect Vapotherm unit to H cylinder and turn flow to 30 LPM via high flow
flow-meter
10. Position adult nasal Vapotherm cannula with clamp stand so that nasal prongs rest
inside double lumen tube
11. After cannula in place cycle ventilator for 1 minute
12. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)
13. Recalibrate Galileo flowsensor
14. Allow to cycle for 1 minute
15. Connect Vapotherm unit to H cylinder and turn flow to 40 LPM via high flow
flow-meter
16. Position adult nasal Vapotherm cannula with clamp stand so that nasal prongs rest
inside double lumen tube
17. After cannula in place cycle ventilator for 1 minute
18. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)
Optiflow

1. Recalibrate Galileo flowsensor
2. Allow to cycle for 1 minute
3. Connect Optiflow unit to H cylinder and turn flow to 20 LPM via high flow flowmeter
4. Position adult nasal Optiflow cannula with clamp stand so that nasal prongs rest
inside double lumen tube
5. After cannula in place cycle ventilator for 1 minute
6. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)
7. Recalibrate Galileo flowsensor
8. Allow to cycle for 1 minute
9. Connect Optiflow unit to H cylinder and turn flow to 30 LPM via high flow flowmeter
10. Position adult nasal Optiflow cannula with clamp stand so that nasal prongs rest
inside double lumen tube
11. After cannula in place cycle ventilator for 1 minute
12. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)
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13. Recalibrate Galileo flowsensor
14. Allow to cycle for 1 minute
15. Connect Optiflow unit to H cylinder and turn flow to 40 LPM via high flow flowmeter
16. Position adult nasal Optiflow cannula with clamp stand so that nasal prongs rest
inside double lumen tube
17. After cannula in place cycle ventilator for 1 minute
18. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)
Generic HFNC

1. Recalibrate Galileo flowsensor

2. Allow to cycle for 1 minute
3. Connect Generic unit to H cylinder and turn flow to 20 LPM via high flow flowmeter
4. Position adult nasal Generic cannula with clamp stand so that nasal prongs rest
inside double lumen tube
5. After cannula in place cycle ventilator for 1 minute
6. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)
7. Recalibrate Galileo flowsensor
8. Allow to cycle for 1 minute
9. Connect Generic unit to H cylinder and turn flow to 30 LPM via high flow flowmeter
10. Position adult nasal Generic cannula with clamp stand so that nasal prongs rest
inside double lumen tube
11. After cannula in place cycle ventilator for 1 minute
12. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)
13. Recalibrate Galileo flowsensor
14. Allow to cycle for 1 minute
15. Connect Generic unit to H cylinder and turn flow to 40 LPM via high flow flowmeter
16. Position adult nasal Generic cannula with clamp stand so that nasal prongs rest
inside double lumen tube
17. After cannula in place cycle ventilator for 1 minute
18. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)
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Appendix B
Protocol
Labored Breathing

1. Power on Galileo Ventilator
2. Run manufacturer flow-sensor calibration
3. Program ventilator with selected parameters
a. Respiratory rate of 24
b. Tidal volume 400
c. Flow of 65LPM
i. Produces I:E of 1:2.8
d. Sine Waveform
e. Oxygen 21%
f. No PEEP
4. Connect ventilator circuit to positive pressure side of test lung
a. Lung compliance set at 0.5 L/cmH2O
5. Activate auxiliary pressure port
a. Connect auxiliary pressure line to front of ventilator
b. Connect auxiliary pressure line to adaptor placed in negative airway
6. Start ventilator and allow to cycle for 1 minute
7. Start Measurement of control with no cannula at the orifice of double lumen tube
Vapotherm

1. Recalibrate Galileo flowsensor
2. Allow to cycle for 1 minute
3. Connect Vapotherm unit to H cylinder and turn flow to 20 LPM via high flow
flow-meter
4. Position adult nasal Vapotherm cannula with clamp stand so that nasal prongs rest
inside double lumen tube
5. After cannula in place cycle ventilator for 1 minute
6. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)
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7. Recalibrate Galileo flowsensor
8. Allow to cycle for 1 minute
9. Connect Vapotherm unit to H cylinder and turn flow to 30 LPM via high flow
flow-meter
10. Position adult nasal Vapotherm cannula with clamp stand so that nasal prongs rest
inside double lumen tube
11. After cannula in place cycle ventilator for 1 minute
12. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)
a. Start recording on breath number 2
b. Record even number breaths for total of 12 recordings (n=12)
13. Recalibrate Galileo flowsensor
14. Allow to cycle for 1 minute
15. Connect Vapotherm unit to H cylinder and turn flow to 40 LPM via high flow
flow-meter
16. Position adult nasal Vapotherm cannula with clamp stand so that nasal prongs rest
inside double lumen tube
17. After cannula in place cycle ventilator for 1 minute
18. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)
a. Start recording on breath number 2
b. Record even number breaths for total of 12 recordings (n=12)
Optiflow

1. Recalibrate Galileo flowsensor
2. Allow to cycle for 1 minute
3. Connect Optiflow unit to H cylinder and turn flow to 20 LPM via high flow flowmeter
4. Position adult nasal Vapotherm cannula with clamp stand so that nasal prongs rest
inside double lumen tube
5. After cannula in place cycle ventilator for 1 minute
6. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)
7. Recalibrate Galileo flowsensor
8. Allow to cycle for 1 minute
9. Connect Optiflow unit to H cylinder and turn flow to 30 LPM via high flow flowmeter
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10. Position adult nasal Vapotherm cannula with clamp stand so that nasal prongs rest
inside double lumen tube
11. After cannula in place cycle ventilator for 1 minute
12. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)
a. Start recording on breath number 2
b. Record even number breaths for total of 12 recordings (n=12)
13. Recalibrate Galileo flowsensor
14. Allow to cycle for 1 minute
15. Connect Optiflow unit to H cylinder and turn flow to 40 LPM via high flow flowmeter
16. Position adult nasal Vapotherm cannula with clamp stand so that nasal prongs rest
inside double lumen tube
17. After cannula in place cycle ventilator for 1 minute
18. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)
a. Start recording on breath number 2
b. Record even number breaths for total of 12 recordings (n=12)
Generic HFNC

1. Recalibrate Galileo flowsensor
2. Allow to cycle for 1 minute
3. Connect Generic unit to H cylinder and turn flow to 20 LPM via high flow flowmeter
4. Position adult nasal Generic cannula with clamp stand so that nasal prongs rest
inside double lumen tube
5. After cannula in place cycle ventilator for 1 minute
6. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)
a. Start recording on breath number 2
b. Record even number breaths for total of 12 recordings (n=12)
7. Recalibrate Galileo flowsensor
8. Allow to cycle for 1 minute
9. Connect Generic unit to H cylinder and turn flow to 30 LPM via high flow flowmeter
10. Position adult nasal Generic cannula with clamp stand so that nasal prongs rest
inside double lumen tube
40

11. After cannula in place cycle ventilator for 1 minute
12. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)
a. Start recording on breath number 2
b. Record even number breaths for total of 12 recordings (n=12)
13. Recalibrate Galileo flowsensor
14. Allow to cycle for 1 minute
15. Connect Generic unit to H cylinder and turn flow to 40 LPM via high flow flowmeter
16. Position adult nasal Generic cannula with clamp stand so that nasal prongs rest
inside double lumen tube
17. After cannula in place cycle ventilator for 1 minute
18. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)
a. Start recording on breath number 2
b. Record even number breaths for total of 12 recordings (n=12)
19. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)
a. Start recording on breath number 2
b. Record even number breaths for total of 12 recordings (n=12)
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